Advancing clinical development pathways for new CFTR modulators in cystic fibrosis

Cystic fibrosis (CF) is a life-shortening genetic disease affecting approximately 70 000 individuals worldwide. Until recently, drug development efforts have emphasised therapies treating downstream signs and symptoms resulting from the underlying CF biological defect: reduced function of the CF tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer-Hamblett, Nicole, Boyle, Michael, VanDevanter, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853537/
https://www.ncbi.nlm.nih.gov/pubmed/26903594
http://dx.doi.org/10.1136/thoraxjnl-2015-208123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853537/
https://www.ncbi.nlm.nih.gov/pubmed/26903594
http://dx.doi.org/10.1136/thoraxjnl-2015-208123

Ejemplares similares